News

Stocktwits on MSN10d
Regeneron Stock Drops On Mixed Results For Smoker’s Lung Treatment
Regeneron Pharmaceuticals (REGN) shares dropped nearly 10% in premarket trading Friday after mixed results from late-stage ...
Clinical Trials Arena on MSN7d
Sanofi and Regeneron report results from two Phase III trials of COPD treatment
Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab in ...
Fierce Biotech10d
Sanofi, Regeneron's IL-33 drug fails one of 2 COPD studies as FDA timeline thrown in doubt
Sanofi’s plans to submit itepekimab to regulators for approval this year have been thrown into doubt after the ...
Itepekimab Failure A Setback For Sanofi And Regeneron
Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...
Pulmonology Advisor3d
Mixed Results for Itepekimab in Former Smokers With COPD
Topline results were announced from two phase 3 trials evaluating itepekimab in former smokers with inadequately controlled COPD.
Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi SA (NASDAQ:SNY) on Friday announced results from two Phase 3 trials ...
BioPharma Dive10d
Mixed COPD results for Regeneron, Sanofi drug cloud approval chances
Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...
Pharmabiz9d
Sanofi & Regeneron announce itepekimab meet the primary endpoint in one of two COPD phase 3 studies
Sanofi & Regeneron announce itepekimab meet the primary endpoint in one of two COPD phase 3 studies: Paris Saturday, May 31, 2025, 10:00 Hrs [IST] The AERIFY-1 phase 3 study evalu ...